

Prenetics™



**Prenetics™**  

---

**Investor Presentation**

October 2021

---

# Disclaimer

This Presentation has been prepared by Artisan Acquisition Corp. ("SPAC") and Prenetics Group Limited (the "Company") in connection with a potential business combination involving SPAC and the Company (the "Transaction") and is preliminary in nature and solely for information purposes and must not be relied upon for any other purpose.

This Presentation does not constitute (i) an offer or invitation for the sale or purchase of the securities, assets or business described herein or a commitment of the Company or SPAC with respect to any of the foregoing or (ii) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Transaction, and this Presentation shall not form the basis of any contract, commitment or investment decision and does not constitute either advice or a recommendation regarding any securities. Any offer to sell securities will be made only pursuant to a definitive subscription agreement and will be made in reliance on an exemption from registration under the Securities Act of 1933 (the "Securities Act") for offers and sales of securities that do not involve a public offering. This Presentation does not purport to contain all information that may be required or relevant to an evaluation of the Transaction, and you will be responsible for conducting any investigations and analysis that you deem appropriate and for seeking independent advice as to the legal, tax, accounting, financial, credit and other related advice with respect to the Transaction.

SPAC and the Company reserve the right to amend or replace this Presentation at any time but none of SPAC and the Company, their respective subsidiaries, affiliates, legal advisors, financial advisors or agents shall have any obligation to update or supplement any content set forth in this Presentation or otherwise provide any additional information to you in connection with the Transaction should circumstances, management's estimates or opinions change or any information provided in this Presentation become inaccurate.

## Forward-Looking Statements

This Presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, and also contains certain financial forecasts and projections. All statements other than statements of historical fact contained in this Presentation, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of the Company, market size and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" or other similar expressions. All forward-looking statements are based upon current estimates and forecasts and reflect the views, assumptions, expectations, and opinions of SPAC and the Company as of the date of this Presentation, and are therefore subject to a number of factors, risks and uncertainties, some of which are not currently known to us. Some of these factors include, but are not limited to: the success of the new product or service offerings of the Company and its subsidiaries (the "Group"), the Group's ability to attract new and retain existing customers, competitive pressures in the industry in which the Group operates, the Group's ability to achieve profitability despite a history of losses, the Group's ability to implement its growth strategies and manage its growth, the Group's ability to meet consumer expectations, the Group's ability to produce accurate forecasts of its operating and financial results, the Group's internal controls, fluctuations in foreign currency exchange rates, the Group's ability to raise additional capital, media coverage of the Group, changes in the regulatory environments of the countries in which the Group operates, general economic conditions in the countries in which the Group operates, the Group's ability to attract and retain senior management and skilled employees, the success of the Group's strategic alliances and acquisitions, changes in the Group's relationship with its current customers, suppliers and service providers, disruptions to information technology systems and networks, the Group's ability to protect its brand and reputation, the Group's ability to protect its intellectual property, potential and future litigation that the Group may be involved in, taxes or other liabilities that may be incurred or required subsequent to, or in connection with, the consummation of the Transaction. The foregoing list of factors is not exhaustive. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

In light of these factors, risks and uncertainties, any estimates, assumptions, expectations, forecasts, views or opinions set forth in this Presentation should be regarded as indicative, preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of this Presentation and the "Risk Factors" section of the proxy statement/prospectus on Form F-4 relating to the Transaction, which has been confidentially submitted to the U.S. Securities and Exchange Commission ("SEC"), and other documents filed from time to time with SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. SPAC and the Company assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible to predict all risks, or assess the impact of all factors on the Company's business or the extent to which any factor, or combination of factors, may cause the Company's actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition. In addition, the analyses of SPAC and the Company contained herein are not, and do not purport to be, appraisals of the securities, assets or business of the Company, SPAC or any other entity. There may be additional risks that neither SPAC nor the Company presently know or that SPAC and the Company currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's and SPAC's assessment as of any date subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements.

# Disclaimer (Cont'd)

## Industry and Market Data

This Presentation also contains information, estimates and other statistical data derived from third party sources (including Frost & Sullivan). Such information involves a number of assumptions and limitations and due to the nature of the techniques and methodologies used in market research, and Frost & Sullivan cannot guarantee the accuracy of such information. You are cautioned not to give undue weight on such estimates. Neither SPAC nor the Company has independently verified such third party information, and makes no representation, express or implied, as to the accuracy, completeness, timeliness, reliability or availability of such third party information. SPAC and the Company may have supplemented such information where necessary, taking into account publicly available information about other industry participants.

## Use of Projections and Historical Financial Information

The 2019 and 2020 historical financial data included in this Presentation has been derived from Prenetics Limited's 2019 and 2020 financial statements prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS") and are subject to updates based on an ongoing external audit in accordance with the Public Company Accounting Oversight Board standards. In addition, the Company's quarterly financial data included in this Presentation is based on financial data derived from the Company's management accounts that have not been reviewed or audited and are subject to further review and updates.

This Presentation contains financial forecasts for the Company with respect to certain financial results for the Company's fiscal years 2021 through 2025 for illustrative purposes. Neither SPAC's nor the Company's independent auditors have audited, studied, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, they did not express an opinion or provide any other form of assurance with respect thereto for the purpose of this Presentation. These projections are forward-looking statements and should not be relied upon as being necessarily indicative of future results. In this Presentation, certain of the above-mentioned projected information has been provided for purposes of providing comparisons with historical data. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. While such information and projections are necessarily speculative, SPAC and the Company believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. Accordingly, there can be no assurance that the prospective results are indicative of the future performance of the Company or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved. All subsequent written and oral forward-looking statements concerning the Company and SPAC, the Transaction or other matters and attributable to the Company and SPAC or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

## Non-IFRS Financial Measures

This Presentation also includes references to non-IFRS financial measures, such as the Company's Adjusted EBITDA for 2019 and 2020. Such non-IFRS measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with IFRS. SPAC and the Company believe these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. SPAC and the Company believe that the use of these non-IFRS financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in and in comparing the Company's financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. Management does not consider these non-IFRS measures in isolation or as an alternative to financial measures determined in accordance with IFRS. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-IFRS financial measures.

Additionally, to the extent that forward-looking non-IFRS financial measures are provided, they are presented on a non-IFRS basis without reconciliations due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations.

# Disclaimer (Cont'd)

## **Additional Information**

If the Transaction is pursued, SPAC will be required to file a preliminary and definitive proxy statement, which may include a registration statement, and other relevant documents with the SEC. You are urged to read the proxy statement/prospectus and any other relevant documents filed with the SEC when they become available because, among other things, they will contain updates to the financial, industry and other information herein as well as important information about SPAC, the Company and the Transaction. Shareholders will be able to obtain a free copy of the proxy statement (when filed), as well as other filings containing information about SPAC, the Company and the Transaction, without charge, at the SEC's website located at [www.sec.gov](http://www.sec.gov).

## **Participants in the Solicitation**

SPAC and the Company, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from SPAC's shareholders in connection with the Transaction. A list of the names of such directors and executive officers and information regarding their interests in the Transaction will be contained in the proxy statement when available. You may obtain free copies of the proxy statement as described in the preceding paragraph. The definitive proxy statement will be mailed to shareholders as of a record date to be established for voting on the Transaction when it becomes available.

## **Trademarks**

This Presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this Presentation may be listed without the TM, SM ® or ® symbols, but such references are not intended to indicate, in any way, that SPAC or the Company will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks, trade names and copyrights.

Neither SPAC, the Company, nor any of their respective directors, officers, employees, affiliates, advisors, representatives or agents, make any representation or warranty of any kind, express or implied, as to the value that may be realized in connection with the Transaction, the legal, regulatory, tax, financial, accounting or other effects of the Transaction or the accuracy or completeness of the information contained in this Presentation, and none of them shall have any liability based on or arising from, in whole or in part, any information contained in, or omitted from, this Presentation or for any other written or oral communication transmitted to any person or entity in the course of its evaluation of the Transaction, and they expressly disclaim any responsibility or liability for direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including lost income or profits and opportunity costs) in connection with the use of the information herein.

By accepting this Presentation, the recipient will be deemed to have acknowledge and agreed to the foregoing.

# Presenters



**Ben Cheng**

*Chief Executive Officer*

**ARTISAN**  
ACQUISITION CORP.



**Danny Yeung**

*CEO & Co-Founder*

**Prenetics™**



**Stephen Lo, CPA, CFA**

*Chief Financial Officer*

**Prenetics™**

**Prenetics™**



# Adrian Cheng Led Team Backed by Inspirational Independent Directors

## ARTISAN ACQUISITION CORP.



**Dr. Adrian Cheng**

Founder of Artisan Acquisition Corp.



**Ben Cheng**

Chief Executive Officer of Artisan Acquisition Corp.



**William Keller**

Independent Director



**Mitch Garber, C.M.**

Independent Director



**Frank Yu**

Independent Director



**Sean O'Neill**

Independent Director





# Prenetics is a Clear Fit for Artisan Acquisition Corp.

## Target Criteria – Clearly Met by Prenetics

- ☑ Focus on disruptive lifestyle technologies in healthcare, consumer, technology
- ☑ Strong fundamentals with significant value creation opportunities
- ☑ Well-positioned to deliver value and synergies in the group's global cultural ecosystem
- ☑ Growth upsides through tapping global consumers' unmet demands & burgeoning markets

**Prenetics™**  
Investment Thesis for  
**ARTISAN**  
ACQUISITION CORP.

1

**Disrupting & decentralizing** global healthcare with large global opportunity of over **US\$1.3tn<sup>1</sup>**

2

**Strong R&D and product innovation capabilities** backed by experienced in-house team, strategic collaboration with Oxford University and vibrant **scientific ecosystem**

3

**First-mover advantage** in target geographies with **robust product pipeline and high growth potential**; well positioned to replicate U.S. success stories in its target geographies

4

**Inspirational founder** backed by **strong leadership team** of tech, biotech, healthcare and consumer veterans

5

**Strong financial profile and highly attractive expected valuation** relative to peers

**Prenetics™**

6

Source: Frost & Sullivan.

Notes: 1. Global opportunity as of 2030; represents global market sizes and target addressable markets, except for colorectal cancer screening which does not include mainland China.

# Significant Synergies - Prenetics and Adrian Cheng's Ecosystem

## Significant Synergies

- Healthcare channel and user access
- Broad network of locations covering healthcare, retail, hospitality and other sectors
- Extensive customer, user, and fan base across platforms
- Direct corporate use cases across eco-system







# PRENETICS

Decentralizing Healthcare

Prevention,  
Diagnostics and  
Personalized Care

---

**Prevention**



Consumer genetic testing and early colorectal cancer screening

Global Opportunity: **US\$117 Billion+<sup>1</sup>**

**Personalized Care**



Personalized nutrition, hair & sexual health products

Global opportunity: **US\$376 Billion+<sup>2</sup>**



**Diagnostics**



Covid-19 testing, POCT / At-home diagnostic testing and medical genetic testing

Global opportunity: **US\$849 Billion+<sup>3</sup>**

**Leading**  
Diagnostics / DNA testing company in HK and UK

**11 Labs**  
7 mobile / airport labs in HK & UK, and 4 fixed labs

**700+**  
Total Employees

**6M+**  
Total tests processed<sup>1</sup>

**\$85M**  
Lifetime Fundraising

**\$205M**  
2021E Revenue

# Prenetics™ Competitive Moat

## Prevention

**Circle DNA** Whole exome sequencing with proprietary 31mm DNA datapoint algorithm

**COLOCLEAR** The only NMPA approved non-invasive FIT-DNA colorectal cancer screening test

**Project Screen by Prenetics** Covid-19 PCR test enabled by in-house developed, cloud-based, automated end-to-end solution with capability to perform over 40K tests daily

## Diagnostics

**OX-LAMP** Covid-19 rapid testing developed by the University of Oxford, utilizing NAAT

**Circle HealthPod** Patent pending POC & at-home rapid detection health monitoring system (e.g. Covid-19 & other infectious disease testing<sup>2</sup>)

**Circle SnapShot** On-going development on at-home blood based testing for routine health check

Notes: 1. Include CircleDNA and Covid-19 tests; as of October 31, 2021.  
2. Assays to test other infectious diseases are currently under development.

# Strategic R&D Collaboration with Oxford University

## OSCAR – Oxford Suzhou Centre for Advanced Research

- Key research directly with the only overseas research centre by Oxford
- Initial focus will be on
  - a) HealthPod general development
  - b) HealthPod for Clinicians development



## Prenetics Molecular Diagnostics Research Center at Oxford University

- Combined research with Oxford University enables Prenetics to have its own research centre at Oxford University
- Prenetics R&D team already works closely with Oxford team of Professors, with collaboration further enabling us to commercialize novel inventions
- Prenetics' ROFR to acquire technology / IP

## Oxford University 3-Year Research Grant

- Key research directly with Oxford and the team of professors from March 2021
- Initial focus:
  - a) Improving sensitivity and time to results of Covid-19 reagent
  - b) Development of enzymes to lower cost
  - c) Assay development (e.g. Infectious disease, STD)



11 Dame Caroline Wilson (British ambassador to China) at OSCAR opening – June 2021

## Close Collaboration with Prenetics In-house R&D Teams

 <p><b>Dr. Lawrence Tzang, Ph.D.</b> Co-founder &amp; Chief Scientific Officer <b>Scientific &amp; Laboratory</b> team</p>	 <p><b>Dr. Senthil Sunderam, M.D.</b> Chief Clinical Officer <b>Clinical &amp; Bioinformatician</b> team</p>
 <p><b>Dr. Mike Ma, Ph.D.</b> Head of R&amp;D <b>Clinical R&amp;D</b> team</p>	 <p><b>Dr. Peter Wong, DPhil</b> Chief Technology Officer <b>Engineering &amp; Development</b> team</p>
 <p><b>Frank Ong, MD</b> Chief Medical Officer <b>Circle Snapshot</b> R&amp;D &amp; Setup</p>	

Prenetics®



# World-class Leadership Team of Tech, Biotech, and Healthcare Pioneers

## Management Team



**Danny Yeung**

CEO & Co-Founder

GROUPON | SXE VENTURES



**Stephen Lo, CPA, CFA**

Chief Financial Officer

Citi | EY



**Lawrence Tzang, PhD**

Chief Scientific Officer & Co-Founder

CityU



**Avi Lasarow**

CEO – EMEA

DNAfit | Citi



**Mike Ma, PhD**

Head of R&D

ENACT SCIENCES | HOLOGIC



**Frank Ong, MD**

Chief Medical Officer

EverlyWell | illumina

## Key Scientific Advisers



**Prof. Zhanfeng Cui**

Donald Pollock Professor of Chemical Engineering, University of Oxford



**Prof. Wei Huang**

Associate Professor in Dept. of Engineering Science, University of Oxford



**Dr. Monique Andersson**

Medical Advisor, Director of Microbiology, Oxford University Hospitals, NHS Foundation Trusts



**Prof. Michael Yang**

Chair Professor of Biomedical Sciences, Vice-President (R&D) City University of Hong Kong



Prenetics™





# Prenetics Current Product Portfolio

---



# Prevention



## Leading Brand

In Asia and UK consumer genomics

45-50x

More data than the competitors

120k+

CircleDNA tests delivered since July 2019 launch

\$16bn+

Global Market Size<sup>1</sup>

\$19mm

2021E CircleDNA Projected Revenue

34%

2020A-2025E Revenue CAGR

## CircleDNA The World's Most Comprehensive Consumer DNA Test


Source: Frost & Sullivan. Notes: 1. Global market size for DTC molecular testing services based on projection for 2030; Covid-19 testing service market is not included while influence of Covid-19 has been considered in the market sizing.

# CircleDNA – An All-New Industry Standard in Genetic Testing

## Genotyping Technology

- **High false negative rate:** Will miss >90% mutations associated with cancer and disease
- **Pre-defined** and specific SNP Readings
- **Limited Data**, can only resolve single letter “typos”
- **Static**, will need to test again as science evolves

## DNA Data Points



## Our Next Generation - Whole Exome Technology

- Read protein-coding genes
- Clinical-grade consumer testing
- 45–50x more data over genotyping
- One test, a Lifetime of Value
- Identify up to 90% genetic variants associated with cancer and other disease



# CircleDNA – the Forefront of Health Diagnostics & Disease Prevention Covering Screening, Wellness, Proactive and Preventive Measures

## 500+ Reports Discovered Across 20 Categories


Family Planning & Disease  
375 reports

Diet, Wellness, Lifestyle  
69 reports

Traits  
70 reports



## A Snapshot of CircleDNA Tests



Prenetics™

# CircleDNA Product Offering



## Vital

- 14 Categories – 125 Reports
- Diet, Nutrition, Fitness, Stress, Ancestry, Skin, and More
- 30 Mins Phone Consultation

USD 189



## Family Planning

- 1 Category – 163 Reports
- Carrier Screening of recessive genetic diseases
- 30 Mins Phone Consultation

USD 499



## Health

- 4 Categories – 115 Reports
- Cancer, Common Health Risks, Disease Risks, Dementia & Brain Health
- 30 Mins Phone Consultation

USD 499



## Premium

- 20 Categories – 500+ Reports
- Vital + Family Planning + Health Bundle + Drug Response
- 30 Mins Phone Consultation (2x)

USD 629

Retail Price

17

Prenetics™



# CircleDNA Marketing Strategy

## Celebrity Ambassadors



**Vaness Wu**  
Actor & singer

**15M+**  
social media followers



**G.E.M.**  
Asia's Taylor Swift

**50M+**  
social media followers



**Gigi Leung**  
Actor, singer & mother

**20M+**  
social media followers

## ATL Marketing



**TRAM**



**WATSONS**



**TAXI**



**BILLBOARD**

## Social Media




**Prenetics™**

# CircleDNA – Extraordinary Growth with Significant Runway

## Forecasted Growth Trajectory after Launch<sup>1</sup>

(# of Cumulative Tests Sold, '000)



**Market Size<sup>4</sup>**

**US\$8.8 bn**

APAC / EMEA  
Consumer DNA Test


**Market Size<sup>4</sup>**

**US\$5.1 bn**

US Consumer DNA Test

## CircleDNA Revenue

(US\$ millions)



19

Source: Frost & Sullivan, Trust Pilot Review.

Notes: 1. Blue dotted line denotes management forecast; grey dotted line is extrapolation of 23andMe. 2. Market data as of August 31, 2021. 3. As of July 12, 2021.

4. Market size for DTC molecular testing services based on projection for 2030; Covid-19 testing service market is not included while influence of Covid-19 has been considered in the market sizing.

**Prenetics™**

# Diagnostics



Prenetics laboratory inside Hong Kong International Airport

**6M+**

Covid-19 Molecular Test Performed<sup>1</sup>

**11 Labs**

7 Mobile / Airport Labs in HK & UK, and 4 Fixed Labs

**\$32bn+**

Global Market Size<sup>2</sup>

**\$51mm**

2020A Covid-19 Testing Revenue

**77%**

2020A-2022E Revenue CAGR

**Blue Chip**

Clientele of Governments & Corporates

## Project Screen Covid-19 Testing

Source: Frost & Sullivan.

Notes: 1. As October 31, 2021. 2. Based on projection for 2021; represents global market size; only consists of tests performed in independent clinical laboratories.

# Prenetics Response To Covid-19

## Key Highlights

### HK Government

- ~3M tests serviced for HK government as of 2Q 2021
- ✓ Community Testing
- ✓ Hospital Authority
- ✓ Department of Health
- ✓ Food and Environmental Hygiene Department (FEHD)



### English Premier League

- Provides daily testing service for more than **3,000 players and club staffs** for English Premier League on a regular basis



### Airport Testing to International & Local Airports

- Airport testing in Hong Kong and the United Kingdom, including **HKIA<sup>1</sup>, Heathrow, Manchester, Stansted, London City, and East Midlands airports**
- Converted smoking lounge to an ISO-15189 **laboratory at the HKIA<sup>1</sup>**. Prenetics is the **only** Covid-19 testing provider with **operating lab in HKIA<sup>1</sup>**



## Extensive Partnerships Across Sectors

Prenetics<sup>™</sup> + Virgin Atlantic

- **Prenetics has become Virgin Atlantic's preferred at-home testing provider**, with customers able to order a complete end-to-end travel testing bundle, tailored to their destination

### Travel (2022E Revenue \$89M)

Virgin Atlantic, Carnival Cruise Line, Cruise line operation of an entertainment company, Hong Kong International Airport, Heathrow Airport, London Luton Airport, London Stansted Airport, Manchester Airport, Gatwick Airport, London City Airport, East Midlands Airport

### Entertainment & Sports (2022E Revenue \$15M)

English Premier League, Professional Darts Corporation, England and Wales Cricket Board, British Academy Film Awards, Sky TV, Global Media & Entertainment Company, American Film & TV Studio

21 Note: 1. Hong Kong International Airport.

Prenetics<sup>™</sup>

# Significant Upside as Travel “Resumes”

## Covid-19 Testing Revenue Breakdown (US\$ millions)





















22

Source: Frost & Sullivan. Notes: 1. 2020 financials based on management accounts – excludes airline & cruises revenue in EMEA as breakdown is not available. 2. Include entertainment & sports, community testing & screening, corporate B2B testing, etc. 3. Based on projection for 2021; represents global market size; only consists of tests performed in independent clinical laboratories.

Prenetics™



# Major COVID-19 Testing Technologies Comparison


	Nucleic Acid Amplification Test (RT-LAMP)	Nucleic Acid Amplification Test (RT-PCR)	Antigen Test (Proteins)
Speed	 Reaction time: 15 - 20min	 Reaction time: 4 - 6 Hours	 Reaction time: 15 - 30min
Accuracy	 Higher: 96%	 Highest: 99%	 Symptomatic: 90% or above Asymptomatic: 27%
Mobility & Lab Required	 No Need Laboratory No Lab Technicians	 Need Laboratory Lab Technicians	 No Need Laboratory No Lab Technicians
Availability	 Yes	 Yes	 Yes
Use-Case	 Symptomatic & Asymptomatic	 Symptomatic & Asymptomatic	 Symptomatic (7 days of infection)
Through-put & Scalability	 Highly Scalable	 Not scalable	 Highly Scalable

23 Source: Frost & Sullivan.

PCR-Quality Technology  
from Oxford

Prenetics™


# Game Changing POC / At-Home PCR-Quality Testing Technology from Oxford University



## ✓ Approvals / Recognitions

- ✓ MHRA<sup>2</sup> in UK
- ✓ CE IVD<sup>3</sup> in EU for POC use
- Application for US FDA in process; Expected by 1H 2022

## CNN Inside Oxford Lab Developing 30-minute Coronavirus Test



# Circle HealthPod

Rapid Detection System  
For **Covid-19**

Source: Company Website. Please view Circle HealthPod Product video here: <https://circlepod.co/>.

---

# Diagnostics



Detects Covid-19 with NAAT  
**PCR-Quality Technology**



#### Future Assays:

- Influenza / Flu
- STDs

**<30min**

Time to result

**98.4%<sup>2</sup>**

Concordance with the q-PCR test

**\$849bn+**

Global Market Size<sup>1</sup>

**Mobile & Scalable**

No lab or specialist equipment

**Painless**

Pain-free nasal swab

**CE-IVD Marked**

Expect to receive US FDA EUA by 1H 2022

## Circle HealthPod

A Lab. In Your Pocket

**Official Launch in Hong Kong by End 2021  
Followed by EU, US, and Southeast Asia**

Source: Frost & Sullivan. Notes: 1. Represents global market size for medical device based on the projection for 2030. 2. According to trials done primarily by professors and scientists of University of Oxford.

# Successful Commercialization Case Study: Cue Health

## The Cue Health Monitoring System

- The Cue Health Monitoring System is a fast, compact, highly portable testing platform with high performance and accuracy, utilizing molecular diagnostic technology
- Cue Health's COVID-19 cartridge test is authorized by the US FDA for home use with no prescription in Mar 2021. The company filed for a US IPO on September 1, 2021.

Cue Health awarded \$481 million to scale up production of COVID-19 test: HHS



REUTERS



HHS launches pilot program in five states using rapid Covid test deployed by NBA



### Go-to-Market Strategy: Key Partners & Target Clients

#### Public Sector

US Department of Defense  
Government Agencies

#### Enterprise

Henry Schein  
Fortune 500 Companies

#### Healthcare Provider

Mayo Clinic  
Hospitals / Private Clinics

#### Direct-to-Consumer

E-commerce  
In-store

**Prenetics™**

27 Source: Company Filings, Cue Health Company Website, Bloomberg, Reuters, CNBC.  
Notes: 1. Per Bloomberg, as of December 2020.



# Use Case



## Private Use

- At-home testing
- On the go testing (with portable charger)



## Hospitals & Clinics

- In-patient and out-patient on-site screening
- Regular testing for healthcare workers & family



## Hotels & Apartments

- For hotel guests as a complimentary item for their stay or as a paid in-room service
- Must-have for every homes to for a peace of mind



## Schools

- Rapid testing for schools
- Regular testing for students and teachers



## NGO Community Screen

- Easy and simple test for NGO's
- Regular testing for community members




## Sports & Entertainment

- Rapid at-home testing for attendees
- Regular testing for players and staffs

# Illustrative Representation of Diagnostic-testing Supply Chain

Level of vertical integration varies based on OEM, technology, and platform





# Circle HealthPod B2B Stations

Multiple Circle HealthPods



Circle HealthPod Dashboard

Partners App



# Circle HealthPod Marketing Strategy – Partnering with International Actor Donnie Yen on Extensive ATL Marketing Campaigns

TRAM



MTR



TVC



TAXI



BUS STATION



BILLBOARD



31

Notes: Initial marketing campaign focusing only for Hong Kong market.

Prenetics™



# Imminent Product Launches

---





# Prevention



**96%**

Sensitivity -  
Highly Accurate

**Cost  
Effective**

Comparing to  
Colonoscopy

**Successful  
Model**

Comparable to  
ColoGuard  
in the US

**\$101bn+**

Addressable  
market<sup>1</sup>

## ColoClear

**The Only Non-Invasive Colon  
Cancer Screening Test  
Approved by NMPA**


**Launching in 1H 2022E**

Source: Frost & Sullivan.


Notes: 1. Global target addressable market for colorectal cancer screening based on projection for 2030, except for mainland China; target population is the age group of 40-74 years old.

# Significant Whitespace in Asia Markets Presents Attractive Growth Opportunities

Colorectal Cancer Screening Market in US (2019)



Colorectal Cancer Screening Market in HK & SEA (2019)



Revenue of ColoGuard for Exact Sciences<sup>1</sup> (US\$ mm)



Projected Revenue of ColoClear for Prenetics (US\$ mm)



34

Source: Frost & Sullivan.

Notes: 1. Before Exact Science's acquisition of Genomic Health in November 2019, ColoGuard is the only major revenue source for Exact Sciences. 2. Market data as of August 31, 2021.

**Prenetics™**

# Strategic Technology Transfer from New Horizon to Launch ColoClear

Prenetics™



(Listed on HKEX with market cap of **US\$2.6bn<sup>1</sup>** and FY2020 revenue of US\$10mm)

## Exclusive

**Exclusive** rights granted to sell & process ColoClear in Hong Kong, Macau, and the Philippines; plan to expand to Taiwan and other countries and regions of SE Asia

## 50:50

Under a profit sharing agreement, Prenetics and New Horizon **will equally share gross profits<sup>2</sup>** from sales of ColoClear

## 5+5 Years

**5 years** of initial term renewable for another **5 years** by mutual consent

## Technology Transfer

Completed technology transfer from New Horizon; **certified by New Horizon to perform ColoClear testing at its lab**

## Establishment of Strategic Partnership with New Horizon Health to Commercialize ColoClear

35

Source: Company Filings. Notes: USD/HKD FX rate of 7.78. 1. Market data as of August 31, 2021. 2. Gross profit = Gross Revenue - COGS for products sold - COGS for lab testing services - Sales & Marketing Expenses (including sales incentives and logistics costs).

Prenetics™

# ColoClear – Industry Leading Performance

FIT-DNA has higher sensitivity when comparing with other non-invasive Colon Cancer screening tests.

Non-Invasive Tests	Sensitivity		Specificity	Detection limitations	Sample size needed	Dietary restrictions
	CRC	AA				
<b>gFOBT</b> (Hemoccult II)	40%	12%	98%	Intermittent bleeding	3 bowel movements	Yes
<b>FIT</b> (Faecal Immunochemical Test)	70%	22%	95%	Intermittent bleeding	Single sample	No
<b>EXACT SCIENCES</b> <b>FIT-DNA (ColoGuard)</b>	<b>92%</b>	<b>42%</b>	<b>87%</b>	<b>CRC and AA continuously exfoliate cells</b>	<b>Single sample</b>	<b>No</b>
<b>Prenetics</b> <b>FIT-DNA (ColoClear)</b>	<b>96%</b>	<b>64%</b>	<b>87%</b>	<b>CRC and AA continuously exfoliate cells</b>	<b>Single sample</b>	<b>No</b>

Diagnostic Invasive Test	Sensitivity		Specificity
	CRC	AA	
<b>Colonoscopy</b>	<b>&gt;95%</b>	<b>95%</b>	<b>90%</b>

✓ Closest CRC sensitivity to actual colonoscopy standards

Sensitivity = True positive / (True positive + False negative) \* 100%;  
Specificity = True negative / (True negative + False positive) \* 100%.

36 Source: Company filings, Colorectal cancer development and advances in screening. Clin Interv Aging. 2016 July 19; 967-976.

Prenetics™



# New Launches 2022 & Beyond

---





# Diagnostics



**50+**

Wide Range of  
Tests for  
Everyone

**Painless**

Blood collection  
at home

**Digital Health  
Platform**

Track your Health  
Progress

**Successful  
Model**

Comparable to  
Everlywell,  
Letsgetchecked

**\$6bn+**

Global Market  
Size<sup>1</sup>

## Circle SnapShot

Your annual health check at home

**Launching in 2022E**

Source: Frost & Sullivan.

Notes: 1. Global market size for at-home health testing based on projection for 2030; does not include home testing kits which do not require lab tests; Covid-19 at-home test has not been considered.

# Successful Commercialization Case Study: Everlywell

## Innovative at-home Health Testing

- Everlywell's portfolio of 30+ at-home tests offer simple sample collection and physician-reviewed results and insights sent to your device in 5 to 7 business days
- In March 2021, Everlywell announced its acquisition of PWNHealth and Home Access Health Corp. in a cash and stock deal. The combined companies, re-branded as Everly Health, expects to support more than 20 million people annually in the US

**\$2.9bn**

Valuation<sup>1</sup>

## Popular Everlywell Tests

### Food Sensitivity

Measure body's immune systems' IgG antibody reactivity to 96 foods



### Metabolism

Measure free testosterone, cortisol and TSH levels



### Indoor & Outdoor Allergy

Test for 40 common indoor and outdoor allergens



### Sexually Transmitted Disease

Screens for 7 common sexually transmitted infections



**~\$200mm**

2020 Revenue<sup>1</sup>

39 Source: Everlywell Company Website, Bloomberg.  
Notes: 1. Per Bloomberg news article, as of March 2021.

Prenetics™

# Diagnostics



**20+**

Wide range of tests for everyone

**Next Generation Sequencing**

Advanced Technology

**Successful Model**

Comparable to Invitae, Natera

**\$59bn+**

Global Market Size<sup>1</sup>

## Circle Medical Genetic Testing for Physicians


**Launching in 2023E**

Source: Frost & Sullivan.

Notes: 1. Global market size for clinical molecular test service based on projection for 2030; Covid-19 testing service market is not included while influence of Covid-19 has been considered in the market sizing.

## Significant Growth Potential in Asia / Europe Markets Present Attractive Growth Opportunities

Medical Molecular Testing Market in US (US\$ bn)



Medical Molecular Testing Market in HK / SEA / Europe (US\$ bn)



Revenue for Invitae (US\$ mm)



Projected Revenue of Circle Medical for Prenetics<sup>3</sup> (US\$ mm)



41

Source: Frost & Sullivan.

Notes: 1. Billable volume for 2018 - 2019. Accessioned volume for 2017. 2. Market data as of August 31, 2021. 3. While its geographic scope is not limited to certain regions, it is expected to predominantly generate revenue in Hong Kong, SE Asia and Europe during the projection period.

**Prenetics**

# Personalized Care



## Data-based

Personalized solution based on data analytics

**63%**

of CircleDNA customers want Circle One<sup>1</sup>

## Recurring Revenue

Subscription model

## Cross Selling

Leverage existing CircleDNA customer base

**\$376bn+**

Addressable market<sup>2</sup>

## Circle One / F1x / Fem Testing into personalized care

**Launching in 2023E**

Source: Frost & Sullivan.

Notes: 1. Based on CircleDNA customer survey conducted in Feb 2020. 2. Represents global target addressable market for hair loss and erectile dysfunction and global market size for personalized nutrition based on projection for 2030.



# Successful Commercialization Case Study: Roman

## Roman – Digital Health Clinic for Men

- Roman provides personalized solutions to men for the treatment of erectile dysfunction, hair loss, premature ejaculation, etc.
- Roman's daily vitamins and supplements are available in 4,600+ Walmart stores across the United States



### Bloomberg

Online Pharmacy Ro Is Said to Raise Funds at \$5 Billion Value

Online pharmacy and health technology company Ro has raised \$500 million in new funding, its chief executive officer told Bloomberg News.

### FORTUNE

Telehealth startup Ro partners with Pfizer to give its ED business a boost

### Key Partners

#### Sports & Entertainments

MLB

#### Pharmaceuticals

Pfizer  
Greenstone

#### Retailers

Walmart

#### Healthcare

Ribbon Health  
Quest Diagnostics

**Prenetics™**

43


Source: Roman Company Website, Bloomberg, PR Newswire, Fortune.  
Notes: 1. Per Bloomberg, as of March 2021. Represents the post-money valuation of Ro, the operator of Roman.  
2. Per Bloomberg, as of March 2021. Represents the lifetime fundraising of Ro, the operator of Roman.

# Our Way Forward


---




# Near-term Development of Product Pipeline



# Prenetics Delivering Favorable Metrics vs. US Peers 5 Years Ago



## Tremendous Value Potential for Prenetics to be Unlocked via Synergistic Acquisitions



Prenetics™

## Financial Information


---





# Prenetics Continues To Transform Itself, Now At An Incredible Rate

## Revenue Evolution<sup>1</sup>




49

Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer.  
 1. 2019 and 2020 financials based on audited accounts - Prevention segment revenue includes other service fees and adjustments. 2021 and 2025 financials based on management forecast.

# Driven by Robust Organic Growth and Product Launch Strategies

Revenue in US\$ millions



50


Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer.  
 1. 2019 and 2020 financials based on audited accounts - Prevention segment revenue includes other service fees and adjustments. 2021-2025 financials based on management forecast.

Prenetics™

# COVID-19: An Opportunity to Better Reimagine Healthcare

## Revenue in US\$ millions<sup>1</sup>

We conservatively assumed COVID-19 testing market is not here to stay. Instead, it has allowed us the opportunity to build the tools and expand our platform in order to better serve the new world order of healthcare



- Testing the New Norm
- Self Care a Necessity
- New Technology
- Brand & Trust
- Network
- Time to Market

51

Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer.  
 1. 2019 and 2020 financials based on audited accounts - Prevention segment revenue includes other service fees and adjustments. 2021-2025 financials based on management forecast.

Prenetics™

# High Operating Efficiency Leading to High Growth

Financials in US\$ million <sup>1</sup>	2019A	2020A	1Q21A	2021E	2022E	2023E	2024E	2025E
Revenue	9	65	57	205	272	307	429	640
YoY %	NA	606%	1315%	215%	33%	13%	40%	49%
Gross Profit <sup>2</sup>	3	27	22	85	118	137	185	295
Gross Margin %	33%	41%	39%	41%	43%	45%	43%	46%
Sales & Marketing Expenses <sup>2</sup>	5	6	2	16	41	72	80	107
Research & Development Expenses <sup>2</sup>	2	2	1	30	36	50	64	83
Administrative and Other Expenses <sup>2,3</sup>	9	14	6	19	27	36	48	65
Adjusted EBITDA (Non-GAAP)	(12)	4	12	21	14	(21)	(7)	39
Adjusted EBITDA Margin %	(131%)	7%	21%	10%	5%	(7%)	(2%)	6%
Depreciation and Amortization	2	2	1	8	13	17	20	21
ESOP & Other Non-Operating Expenses <sup>4</sup>	6	4	9	54	16	18	25	37
Net Profit / (Loss)	(20)	(2)	2	(41)	(15)	(56)	(52)	(19)
Net Profit Margin %	(219%)	(3%)	3%	(20%)	(6%)	(18%)	(12%)	(3%)

- Revenue growth driven by robust organic expansion and product launch strategies

- Significant market opportunity in multiple verticals; Pipeline products expected to benefit from customer and operational synergies across platforms

- Significant positive momentum is expected from 2024 onwards as most products are in their high growth stage

## Transaction Overview




# Transaction Summary

## Transaction Overview<sup>1</sup>

- Illustrative enterprise value of \$1.25 billion
- Artisan Acquisition Corp. to merge with Prenetics
  - An implied multiple of 4.6x 2022E Revenue and 4.1x 2023E Revenue
- Concurrent with the transaction, \$60mm raised in the form of forward purchase agreements ("FPAs") from Aspex and PAG, in addition to another \$60mm raised in a PIPE from Lippo, Dragonstone, Xen Capital and others at \$10.00 per share
- 100% of Prenetics existing shareholders roll into the new entity. No existing shareholders are exiting
- Proceeds to be used for strategic acquisition or investments, R&D, product roll out, geographic expansion and general corporate purposes

## Illustrative Ownership<sup>1</sup>



## Illustrative Enterprise Value<sup>1</sup>

Share Price	\$10.00
Shares Outstanding (mm)	170.92
Illustrative Post-Money Equity Value	\$1,709
(-) Net Cash to Balance Sheet <sup>3</sup>	\$455
<b>Illustrative Enterprise Value</b>	<b>\$1,254</b>
EV / 2022E Revenue	4.6x
EV / 2023E Revenue	4.1x

## Illustrative Sources & Uses

Assumes 0% redemption by SPAC Shareholders

Sources		Uses	
Existing Target Shareholder Equity Rollover	\$1,150 <sup>1</sup>	Existing Target Shareholder Equity Rollover	\$1,150 <sup>1</sup>
Sponsor Promote <sup>4</sup>	100	Sponsor Promote <sup>4</sup>	100
Cash Available in SPAC Trust Account	339	Transaction Expenses	40
Forward Purchase Agreement	60	Net Cash to Balance Sheet	419
PIPE	60		
<b>Total Sources</b>	<b>\$1,709</b>	<b>Total Uses</b>	<b>\$1,709</b>

Notes: USD/HKD FX rate of 7.78.

1. Excludes (i) the impact of any equity awards issued at or after the closing of the transaction, (ii) the dilutive impact of 18.7mm warrants (11.3mm SPAC public warrants, 5.9mm of sponsor warrants, 1.5mm of FPA warrants) with a strike price of \$11.50 per share, and (iii) the impact of shares with super-voting rights. Includes 9.98mm total Class B ordinary shares.

2. Includes SPAC directors.

3. Includes net cash to balance sheet of \$419mm post the transaction, and Prenetics balance sheet net cash of \$35.4mm, the pro-forma amount of which includes a cash balance of \$9.4mm as of 1Q 2021 and \$26.0mm of proceeds from pre-IPD fundraising.


4. Includes total 9.13mm Class B ordinary shares held by the Sponsor, 0.75mm Class B ordinary shares held by the FPA providers, and 0.1mm Class B ordinary shares held by SPAC directors.

54

Prenetics



# Sum-of-the-Parts Valuation: Today



Notes: USD/HKD FX rate of 7.78. 1. Prenetics' 2023 net revenue, which takes into account GST and transaction costs, from the management forecast used to calculate the implied sum-of-the-parts valuation. 2. EV/CY2023E revenue calculated based on 2023E total net revenue including net revenue from Project Screen. 3. 23andMe, Invitae, Natera, Exact Sciences and New Horizon Health were referenced for EV/revenue multiples on Prenetics' prevention and personalized care business segment. 4. Autobio Diagnostics, Dr. Pal PathLabs, Invitae, Motropolis Healthcare and Quidel were referenced for EV/revenue multiples on Prenetics' diagnostics business segment. Project Screen business was not taken into account in the valuation of the diagnostics business given the phaseout of the business from 2022 onwards.



# Peers' Proven Successes Supported by Substantial Valuation

	Prenetics Products	Peers <sup>1</sup>	Current Valuation / Market Capitalization <sup>2</sup>
<b>Prevention</b>	 	 	<b>\$3.5bn<sup>3</sup></b> <b>\$2.6bn<sup>3</sup></b>
<b>Diagnostics</b>	  	  	<b>\$2.0bn<sup>4</sup></b> <b>\$2.9bn<sup>5</sup></b> <b>\$6.4bn<sup>3</sup></b>
<b>Personalized Care</b>			<b>\$5.0bn<sup>6</sup></b>

Source: Bloomberg. Notes: 1. Select companies with comparable products focused in the US / China. 2. Market cap for listed companies, or latest private round valuation. 3. Market cap as of August 31, 2021. 4. Valuation reportedly discussed in the latest private round; per Bloomberg, as of December 2020. 5. Valuation after the acquisition of PWNHealth; per Bloomberg, as of March 2021. 6. Post-money valuation for \$500mm fundraising; per Bloomberg, as of March 2021.



# Benchmarking Analysis

## Prenetics



## Prevention / Personalized Care

## Diagnostics

### EV / CY2022E Revenue Multiples



### EV / CY2023E Revenue Multiples



# Select Precedent Transactions

Date	Acquiror	Target	Public / Private	EV <sup>1</sup> (US\$m)	EV/LTM	
					Sales (x)	EBITDA (x)
Apr-21	CA HEALTHCARE	lumiraDx	Private	3,000.0	-	-
Apr-21	DiaSorin Molecular	Luminex	Public	1,624.3	3.9	22.3
Mar-21	Roche	GenMark Dx	Public	1,729.0	10.1	-
Feb-21	VG	ZbandMe	Private	3,500.0	11.5	-
Oct-20	EXACT SCIENCES	Thrive. Factor Detection	Private	1,700.0	-	-
Oct-20	EXACT SCIENCES	base	Private	410.0	-	-
Sep-20	investor	ADVANCED INSTRUMENTS	Private	780.0	10.8	24.1
Sep-20	QIAGEN	NeuMEDx (80%)	Private	309.6	-	-
Jun-20	INVITAE	ARCHER	Private	886.0	17.7	nm <sup>2</sup>
Mar-20	INVITAE	diploid	Private	95.0	-	-
Feb-20	meridian BIOSCIENCE	Eyalenz PROTEOMICS ANALYTICS	Public	51.5	3.8	nm <sup>2</sup>
Jan-20	NEO GENOMICS	HUNTER LOGIC (Oncology)	Private	37.0	3.7	-
	Mean			1,343.5	8.8	23.2
	Median			833.0	10.1	23.2

58 Notes: Public filings, Dealogic and MergerMarket.  
1. Excludes earnout. 2. EV / LTM EBITDA multiple less than 0.0x.

Prenetics™

Appendix



# Dysfunctional “Sick-care As Healthcare” Is Ripe for Disruption

**Reactive** Infrequent passive touch-points with healthcare system

**Late Stage Focus** Focused on treating already sick people

**Vicious Cycle** As more people get sick, they require more resources, leaving fewer resources to keep people healthy

**Ageing Population & Chronic Disease Burden**  
Adding significant burden to healthcare system

**6/10**

of Global Population  
Lives with Two or More  
Chronic Diseases<sup>1</sup>

**1 / 4**

Wastage in US  
Healthcare Spending<sup>2</sup>

**US\$8.8trn**

Global Healthcare  
Spending in 2021<sup>3</sup>

**59%**


% Relative Lifetime  
Healthcare Expenditure  
at Age 65 or Over<sup>4</sup>

## Conventional Healthcare Is No Longer a Viable Solution

Sources & Notes: 1. Adults aged 65 or over in total 27 OECD countries as of 2014. OECD. 2. JAMA. <https://www.healthleadersmedia.com/clinical-care/wasteful-spending-us-healthcare-estimated-760-billion-935-billion>. 3. IHS Markit, <https://ihsmarkit.com/research-analysis/global-healthcare-spend-to-remain-stable.html>. 4. The Lifetime Distribution of Health Care Costs: Borhani Alenayehu, Kenneth E Warner, et al. (June 2004).




# Asia Based, Global Presence



# Key Milestones

● Corporate Events   ● Fundraising




62 Note: Logos under each fundraising round represent the lead / key investors. 1. As of October 2021.

# Digital SnapShot of Your Health

**SnapShot is a user-friendly results delivery system that capitalises on market trends and consumer expectations.**

The device will work to analyse blood markers across health categories including, for example:



63

**SnapShot** is both an off-the-shelf and white-label solution (including API functionality) offering an E2E service.

This includes fulfilling the blood test kits, delivering to the customer including returns, processing of samples and release of results.







Prenetics

# Illustrative SnapShot Tests – Planned Launching in 2022E




# Moving into Medical Genetic Testing (Circle Medical) – Launching in 2023E

Revealing the cause of genetic diseases | Targeted and symptoms-based diagnostic testing

Single Gene Testing	Monogenic Panels	Exome Sequencing	Genome Sequencing
			
<b>Rapid &amp; Low-Cost</b> <b>20 Genes</b>	<b>15+ Specialities</b> <b>500+ Panels</b>	<b>1,000's of</b> <b>Rare Diseases</b>	<b>Most</b> <b>Comprehensive</b>
BRCA1 BRCA2 APOE CYP2C19 CHEK2 FH	Oncology Reproductive Health Neurology Pediatrics Immunology Hematology	Confirm the diagnosis for complex or unclear symptoms Identify or rule out the mutation that causes the symptoms	1,000's of Rare Diseases Point Mutations Structural Variants Complex Mutations Non-Coding Mutations Disease Susceptibility

# Personalized Health Products – Planned to start from 2023





## How It Works



**120K+**  
Customer Data<sup>1</sup>



**31M**  
Genetic Data Points<sup>1</sup>



**Combine Customer  
and Genetic Data**



**Use Algorithm to  
Process the Data**



**Personalized  
Supplements**



**Unspoken  
Needs Solutions**

**Prenetics™**

# Summary Financials

Financials in US\$ million <sup>1</sup>	2019A	2020A	1Q20A	1Q21A	2021E	2022E	2023E	2024E	2025E
<b>Prevention</b>	<b>9</b>	<b>14</b>	<b>4</b>	<b>4</b>	<b>20</b>	<b>31</b>	<b>69</b>	<b>102</b>	<b>159</b>
- Circle DNA	NA	NA	NA	NA	19	21	42	52	62
- ColoClear	-	NA	NA	NA	1	10	27	50	98
- Others	NA	NA	NA	NA	-	-	-	-	-
<b>Diagnostics</b>	<b>-</b>	<b>51</b>	<b>-</b>	<b>54</b>	<b>185</b>	<b>236</b>	<b>215</b>	<b>290</b>	<b>434</b>
- Project Screen	-	51	-	54	173	162	32	6	-
- Circle HealthPod	-	-	-	-	12	56	123	177	243
- Circle SnapShot	-	-	-	-	-	18	35	69	135
- Circle Medical	-	-	-	-	-	-	26	38	56
<b>Personalised Care</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4</b>	<b>23</b>	<b>37</b>	<b>47</b>
<b>Revenue</b>	<b>9</b>	<b>65</b>	<b>4</b>	<b>57</b>	<b>205</b>	<b>272</b>	<b>307</b>	<b>429</b>	<b>640</b>
Prevention <sup>2</sup>	3	5	2	1	9	16	38	57	88
Diagnostics <sup>2</sup>	-	21	(0)	21	76	100	89	109	180
Personalised Care <sup>2</sup>	-	-	-	-	-	2	11	19	26
<b>Gross Profit<sup>2</sup></b>	<b>3</b>	<b>27</b>	<b>2</b>	<b>22</b>	<b>85</b>	<b>118</b>	<b>137</b>	<b>185</b>	<b>295</b>
Total Marketing Expenses <sup>2</sup>	5	6	2	2	16	41	72	80	107
Administrative Expenses <sup>2</sup>	9	14	2	6	19	27	36	48	65
Research & Development Expenses <sup>2,3</sup>	2	2	0	1	30	36	50	64	83
<b>Adjusted EBITDA</b>	<b>(12)</b>	<b>4</b>	<b>(2)</b>	<b>12</b>	<b>21</b>	<b>14</b>	<b>(21)</b>	<b>(7)</b>	<b>39</b>
Depreciation and Amortization	2	2	0	1	8	13	17	20	21
<b>Adjusted EBIT</b>	<b>(14)</b>	<b>2</b>	<b>(3)</b>	<b>11</b>	<b>13</b>	<b>1</b>	<b>(38)</b>	<b>(26)</b>	<b>18</b>
Net interest expense	0	0	0	0	(0)	0	0	0	0
Other expense / (income)	0	(0)	0	(1)	-	-	-	-	-
ESOP	4	2	1	0	12	16	18	25	37
<b>Net Operating Profit / (Loss)</b>	<b>(18)</b>	<b>1</b>	<b>(4)</b>	<b>11</b>	<b>1</b>	<b>(15)</b>	<b>(56)</b>	<b>(52)</b>	<b>(19)</b>
Other Non-Operating Expense	3	5	0	7	41	-	-	-	-
<b>Profit / (Loss) before taxation</b>	<b>(21)</b>	<b>(4)</b>	<b>(4)</b>	<b>4</b>	<b>(41)</b>	<b>(15)</b>	<b>(56)</b>	<b>(52)</b>	<b>(19)</b>
Income Tax / (Credit)	(1)	(2)	(3)	2	0	-	-	-	-
<b>Net Profit / (Loss)</b>	<b>(20)</b>	<b>(2)</b>	<b>(1)</b>	<b>2</b>	<b>(41)</b>	<b>(15)</b>	<b>(56)</b>	<b>(52)</b>	<b>(19)</b>

68


Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer.

1. 2019 and 2020 financials based on audited accounts except by-product revenues which are based on management accounts. 2021-2025 financials based on management forecast.  
2. Excludes depreciation and amortization expenses. 3. Profit sharing to New Horizon for ColoClear is also included.

Prenetics<sup>®</sup>

# Conservative Cash Management & CAPEX Planning


## Cash Burn Rate in US\$ millions



- Cash burn rate (from operating and investing activities) averaging at US\$43 million per year in 21-25E
- Continuous R&D and product commercialization efforts help position company for growth and profitability in the long-term
- Strong fundraising track record to support the financing of company's business expansion plans

## CAPEX in US\$ millions

% of Revenue



- Large increase in CapEX expected from 22-24E to budget for IP acquisition in relation to R&D technology
- Expected decrease in CapEX as a percentage of revenue as new product offerings continue to mature

# Product Portfolio Summary

Product	Launch Date	IP Ownership	Developed Product In-House	Distribution Exclusivity	Distribution Region <sup>1</sup>	Current Consumer Base
<b>Circle DNA</b>	July 2019	Yes	Yes	Yes	Asia, EMEA	120k+ tests delivered since 2019 launch
<b>ColoClear</b>	1H 2022E	Technical transfer from New Horizon Health	No	Yes	SE Asia, HK, Taiwan, Macau, Philippines	N/A
<b>Project Screen</b>	2020	Yes	Yes	Yes	HK, UK	5 million+ covid-19 molecular tests performed
<b>Circle HealthPod</b>	2021	Yes	In collaboration with Oxford University	Yes	Asia, EMEA	N/A
<b>Circle SnapShot</b>	2022E	Yes	Yes	Yes	Asia, EMEA	N/A
<b>Circle Medical</b>	2023E	Yes	Yes	Yes	Asia, EMEA	N/A
<b>Circle One</b>	2023E	Yes	Yes	Yes	Asia, EMEA	N/A

# Risks Relating to Prenetics's Business

## Key Risks Relating to Prenetics's Business

1. A significant portion of Prenetics's historical revenue was, and its near-term revenue will be generated, from its COVID-19 testing services, the demand for which may be substantially reduced with the production and widely administered use of an efficacious vaccine or treatment for COVID-19, and failure of Prenetics to derive significant revenue from other products and services and expand its overall customer base would harm its business and results of operation.
2. The diagnostic testing market, particularly with respect to COVID-19 testing, is highly competitive, and many of Prenetics's competitors are larger, better established and have greater financial and other resources.
3. The consumer genetic testing market is highly competitive, and many of Prenetics's competitors are more established and have stronger marketing capabilities and greater financial resources, which presents a continuous threat to the success of its consumer genetic testing business.
4. Prenetics's near-term success is highly dependent on the successful launch of Circle HealthPod and the continued commercialization of its COVID-19 testing services in its target geographies. If Prenetics's existing or new products are unable to attain market acceptance or be successfully commercialized in all or any of these jurisdictions, its business and future prospects could be materially and adversely affected.
5. Prenetics relies substantially on third-party contract manufacturers for the manufacturing, quality-testing, assembly and shipping of its COVID-19 test kit, Circle HealthPod and other products. Any termination of significant rights under the existing arrangements would disrupt Prenetics's ability to sell and distribute its COVID-19 test kit, Circle HealthPod and other products until and unless it finds new contract manufacturers, which would materially and adversely affect its business.
6. Prenetics has a number of pipeline products that are currently in the R&D phase, including Circle Medical, Circle SnapShot, future assays of Circle HealthPod, Circle One and F1x and Fem, and may not be successful in its efforts to develop any of these or other products into marketable products. Any failure to develop these or other products or any delay in the development could adversely affect its business and future prospects.
7. Clinical trials, and verification and validation studies necessary to support a future product submission with regulatory authorities will be expensive and may require the enrollment of large numbers of subjects or the availability of a large number of test samples, and suitable subjects or samples may be difficult to identify and recruit or obtain. Delays or failures in Prenetics's clinical trials will prevent it from commercializing any modified or new products and will adversely affect its business, operating results and prospects.
8. If the third parties engaged by Prenetics to conduct clinical trials fail to render their services as contractually required or expected, Prenetics may not be able to obtain regulatory approval for or commercialize its products.
9. If Prenetics is not successful in leveraging its platform and technology to discover, develop and commercialize additional products, its ability to expand its business and achieve its strategic objectives would be impaired.
10. If Prenetics's products and services do not deliver reliable results as expected, its reputation, business and operating results will be adversely affected.

## Other Risks Relating to Prenetics's Business

1. Prenetics has incurred net losses since its inception, and it anticipates that it will continue to incur losses for the foreseeable future, which could harm its future business prospects.
2. Prenetics is an early-stage company and has a limited operating history, and its near-term business strategy and in-house R&D efforts are centered around new and rapidly developing markets including point-of-care testing (POCT) for infectious diseases diagnosis, which may make it difficult to evaluate its current business and predict its future performance.
3. Prenetics has a limited history introducing new products and services to its customers. The future prospects of its business may be harmed if Prenetics's efforts to attract new customers and engage existing customers by introducing new products, including Circle HealthPod, are unsuccessful.
4. Prenetics may not be able to achieve or maintain satisfactory pricing and margins, and its pricing strategies may not meet customers' price expectations, which could adversely affect its revenues and results of operations.
5. Prenetics has increased, and expects to further expand, the size of its organization, and it may experience difficulties in managing its growth. If Prenetics is unable to manage the anticipated growth of its business, its future revenue and operating results may be harmed.
6. The initial use of Prenetics's test kits requires users to follow instructions, and not adhering to instructions may lead to false results and inaccurate outcomes, which could harm the user experience and customer perception of Prenetics's products.
7. Some of Prenetics's marketing initiatives, including celebrity and key opinion leader endorsement and use of social media, may adversely affect Prenetics's reputation.
8. Prenetics relies substantially on its research collaboration with Oxford for development and commercialization of its POCT infectious disease testing products. If Oxford is unable to achieve projected development milestones or produce any meaningful research results, or experiences delays in doing so, Prenetics may not be able to capitalize on its investment in the collaboration projects and its business and reputation may be adversely affected.
9. Prenetics relies on a limited number of suppliers for Circle HealthPod components, COVID-19 test kit materials and laboratory testing services for COVID-19 test kit and CircleDNA, and may not be able to find replacements or immediately transition to alternative suppliers, which could adversely affect its ability to meet customer demand.
10. The operating results of Prenetics may fluctuate significantly, which makes its future operating results difficult to predict and could cause its operating results to fall below expectations.
11. Prenetics's business significantly depends upon the strength of Prenetics's brands, including Prenetics, CircleDNA and Circle HealthPod, and any harm to Prenetics's brands or reputation may materially and adversely affect its business and results of operations.
12. If Prenetics cannot provide quality technical and customer and user support, it could lose customers, and its business and prospects may be adversely affected.
13. If Prenetics is unable to successfully expand its sales and marketing infrastructure to match its growth, its business may be adversely affected.
14. Prenetics is highly dependent on its senior management team and key advisors and personnel, and its business and operating results could be harmed if it is unable to retain senior management and key personnel and to attract and retain qualified personnel necessary for its business.

# Risks Relating to Prenetics's Business (Cont'd)

## Other Risks Relating to Prenetics's Business (Cont'd)

15. The sizes of the markets and forecasts of market growth for the demand of Prenetics's current and pipeline products and services are based on a number of complex assumptions and estimates that are subject to change, and may be inaccurate.
16. Prenetics may need to raise additional funds to develop its platform, commercialize new products or expand its operations, and it may be unable to raise capital when needed or on acceptable terms.
17. Prenetics plans to enter new business areas, such as clinical genetic testing and personalized care, where Prenetics does not have any experience or has minimal experience. Prenetics would likely face competition from entities more familiar with those businesses, and Prenetics's efforts may not succeed.
18. Prenetics may engage in acquisitions, investments or strategic alliances in the future, which could require significant management attention and resources, may not achieve their intended results and could adversely affect its business, financial condition and results of operations.
19. Prenetics may incur debt or assume contingent or other liabilities or dilute Prenetics's shareholders in connection with acquisitions or strategic alliances.
20. If PubCo fails to implement and maintain an effective system of internal controls in the future, PubCo may be unable to accurately report its financial condition or results of operations, which may adversely affect investor confidence in Prenetics and, as a result, the market price of PubCo Ordinary Shares and PubCo Warrants.
21. U.K.'s withdrawal from the European Union could have an adverse impact on Prenetics's business.
22. If Prenetics, its suppliers or its contract manufacturers experience any significant business disruptions, Prenetics's operations and financial condition could be seriously harmed.
23. Prenetics depends on the information systems of its own and those of third parties for the effective service on Prenetics's website, mobile applications, or in Prenetics's computer or logistics systems, and the overall effective and efficient functioning of its business. Failure to maintain or protect Prenetics's information systems and data integrity effectively could harm Prenetics's business, financial condition and results of operations.
24. The COVID-19 pandemic could materially and adversely affect Prenetics's business and results of operations.

## Risks Relating to Doing Business in Hong Kong

1. The business, financial condition and results of operations of Prenetics, and/ or the value of PubCo Ordinary Shares or PubCo's ability to offer or continue to offer securities to investors may be materially and adversely affected to the extent the laws and regulations of the PRC become applicable to Prenetics.
2. The PRC government has significant oversight and discretion over the manner in which companies incorporated under the laws of PRC must conduct their business activities. Although Prenetics is a Hong Kong-based company with no material operations in mainland China, if it were to become subject to such oversight or discretion, there may be a material change in its operations and/ or the value of PubCo's securities, which would materially affect the interests of the investors.
3. Implementation of the National Security Law in Hong Kong involves uncertainty, and the recent policy pronouncements by the PRC government regarding business activities of U.S.-listed Chinese businesses may negatively impact Prenetics's existing and future operations in Hong Kong.
4. PubCo's securities may be delisted under the Holding Foreign Companies Accountable Act if the PCAOB were unable to inspect or fully investigate Prenetics's auditor. The delisting of PubCo's securities, or the threat of their being delisted, may materially and adversely affect the value of your investment. Additionally, if the PCAOB were unable to conduct inspections or investigations of Prenetics's auditor, it would deprive PubCo's investors with the benefits of such inspections.
5. Prenetics may be affected by the currency peg system in Hong Kong and other exchange rate fluctuations.
6. Increases in labor costs may adversely affect Prenetics's business and results of operations.
7. Unfavorable economic and political conditions in Hong Kong and other parts of Asia could materially and adversely affect Prenetics's business, financial condition, and results of operations.

## Risks Relating to Government Regulation

1. Prenetics's business collects and processes a large amount of data including personal information, and Prenetics will face legal, reputational, and financial risks if Prenetics fails to protect its customers' data from security breaches or cyberattacks. Prenetics is also subject to various laws and regulations relating to privacy or the protection or transfer of data relating to individuals, and any change in such laws and regulations or any failure by Prenetics to comply with such laws and regulations could adversely affect Prenetics's business.
2. Prenetics's products and services are and will continue to be subject to extensive regulation, compliance of which could be costly and time-consuming or may cause unanticipated delays or prevent the receipt of the required approvals to offer Prenetics's products and services.
3. Prenetics's testing products are subject to various regulatory guidelines, and any identified deficiencies or quality issues in the components of the test kits and testing devices could result in product recalls and could harm its reputation, business and financial results.
4. Prenetics plans to expand its business and operations internationally to various jurisdictions in which it does not currently operate and where Prenetics has limited operating experience, all of which exposes Prenetics to business, regulatory, political, operational and financial risk.



# Risks Relating to Prenetics's Business (Cont'd)


## Risks Relating to Intellectual Property and Legal Proceedings

1. Prenetics may be subject to legal proceedings and litigation, which are costly to defend, and adverse publicity about any investigation, litigation, regulatory or legal action against Prenetics or its senior management could harm its reputation and business.
2. Prenetics's patent and other intellectual property protection may not be sufficient, and if Prenetics is unable to obtain, maintain and protect its intellectual property rights and proprietary information or prevent thirdparties from making unauthorized use of its technology, its business could be harmed.
3. Prenetics depends, and may depend in the future, on intellectual property licensed from third parties for development and commercialization of certain products, and the termination of the licenses or other agreements permitting Prenetics to use such intellectual property or failure of such third parties to maintain or protect such intellectual property could result in the loss of significant rights by Prenetics, which would harm its business.
4. Prenetics could be sued for products liability, which could result in substantial liabilities that exceed its resources.
5. Prenetics may be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that Prenetics's employees have wrongfully used or disclosed alleged trade secrets of their former employers.
6. The diagnostic testing industry is characterized by intellectual property litigation and in the future Prenetics may be involved in patent litigation or other intellectual property infringement claims or administrative proceedings with respect to intellectual property that could be costly, result in the diversion of management's time and efforts, and may disrupt its business and operations.
7. Patent terms may be inadequate to protect Prenetics's competitive position on its products and services for an adequate amount of time.
8. Prenetics uses open source software, which may pose particular risks to its proprietary software and source code. Prenetics may face claims from open source licensors claiming ownership of, or demanding the release of, the intellectual property that it developed using or derived from such open source software.
9. Prenetics relies substantially on its trademarks and trade names. If its trademarks and trade names are not adequately protected, then Prenetics may not be able to build name recognition in its markets of interest and its business may be harmed.

# Transaction Structure


## Reorganization Steps

### Step 1




- New Cayman Listco and Merger Sub 1 are formed\*\*
- Merger Sub 1 merges into Artisan SPAC
- Outstanding Artisan SPAC stock and warrants cancelled in exchange for New Listco stock and warrants
- Transaction is intended to qualify for Artisan SPAC security holders as a § 368(a)(1)(F) tax-free reorganization for U.S. federal income tax purposes

### Step 2



- Listco forms Cayman Merger Sub 2
- Merger Sub 2 merges into Prenetics Group, with Prenetics Group surviving
- Outstanding Prenetics Group stock cancelled in exchange for Listco stock
- Share exchange is intended to qualify as tax-free for U.S. federal income tax purposes under § 368(a); may also qualify under § 351 depending on size of Prenetics shareholders' percentage ownership of Listco

### Resultant Transaction





## **Forward-Looking Statements**

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are based on beliefs and assumptions and on information currently available to Artisan Acquisition Corp. (“Artisan”) and Prenetics Group Limited (“Prenetics”) and also contains certain financial forecasts and projections.

All statements other than statements of historical fact contained in this document, including, but not limited to, statements as to future results of operations and financial position, Prenetics’ plans for new product development and geographic expansion, objectives of management for future operations of Prenetics, projections of market opportunity and revenue growth, competitive position, technological and market trends, the sources and uses of cash from the proposed transaction, the anticipated enterprise value of the combined entity (“PubCo”) following the consummation of the proposed transaction, anticipated benefits of the proposed transaction and expectations related to the terms of the proposed transaction, are also forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. These statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of Artisan and Prenetics, which involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Any such estimates, assumptions, expectations, forecasts, views or opinions, whether or not identified in this document, should be regarded as indicative, preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. Although each of Artisan, Prenetics and PubCo believes that it has a reasonable basis for each forward-looking statement contained in this document, each of Artisan, Prenetics and PubCo caution you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form F-4 relating to the proposed transaction, which has been filed by PubCo with the U.S. Securities and Exchange Commission (the “SEC”) and other documents filed by Artisan or PubCo from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements in this document include statements regarding the proposed transaction, including the timing and structure of the transaction, the proceeds of the transaction and the benefits of the transaction. Neither Artisan, Prenetics nor PubCo can assure you that the forward-looking statements in this document will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including the ability to complete the business combination due to the failure to obtain approval from Artisan’s shareholders or satisfy other closing conditions in the business combination agreement, the occurrence of any event that could give rise to the termination of the business combination agreement, the ability to recognize the anticipated benefits of the business combination, the amount of redemption requests made by Artisan’s public shareholders, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations as a result of the announcement and consummation of the transaction, the outcome of any potential litigation, government or regulatory proceedings and other risks and uncertainties, including those to be included under the heading “Risk Factors” in the registration statement on Form F-4 that has been filed by PubCo to the SEC and those included under the heading “Risk Factors” in the final prospectus of Artisan dated May 13, 2021 and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Artisan, Prenetics, PubCo, their respective directors, officers or employees or any other person that Artisan, Prenetics or PubCo will achieve their objectives and plans in any specified time frame, or at all. The forward-looking statements in this document represent the views of Artisan, Prenetics and PubCo as of the date of this document. Subsequent events and developments may cause those views to change. However, while Artisan, Prenetics and PubCo may update these forward-looking statements in the future, Artisan, Prenetics and PubCo specifically disclaim any obligation to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of Artisan, Prenetics or PubCo as of any date subsequent to the date of this document. Accordingly, undue reliance should not be placed upon the forward-looking statements.

---

**Important Additional Information Regarding the Transaction Will Be Filed With the SEC**

In connection with the proposed transaction, PubCo has filed a registration statement on Form F-4 (the "Registration Statement") with the SEC that includes a prospectus with respect to PubCo's securities to be issued in connection with the proposed transaction and a proxy statement with respect to the shareholder meeting of Artisan to vote on the proposed transaction. Shareholders of Artisan and other interested persons are encouraged to read, when available, the preliminary proxy statement/prospectus as well as other documents to be filed with the SEC because these documents will contain important information about Artisan, Prenetics and PubCo and the proposed transaction. After the Registration Statement is declared effective, the definitive proxy statement/prospectus to be included in the registration statement will be mailed to shareholders of Artisan as of a record date to be established for voting on the proposed transaction. Once available, shareholders of Artisan will also be able to obtain a copy of the Registration Statement, including the proxy statement/prospectus, and other documents filed with the SEC without charge, by directing a request to: Artisan Acquisition Corp., Room 1111, New World Tower 1, 18 Queen's Road, Central, Hong Kong. The preliminary and definitive proxy statement/prospectus to be included in the Registration Statement, once available, can also be obtained, without charge, at the SEC's website ([www.sec.gov](http://www.sec.gov)).

**Participants in the Solicitation**

Artisan, Prenetics and PubCo and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the potential transaction described in this document under the rules of the SEC. Information about the directors and executive officers of Artisan and their ownership is set forth in Artisan's filings with the SEC, including its final prospectus dated May 13, 2021 and subsequent filings on Form 10-Q and Form 3. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of Artisan's shareholders in connection with the potential transaction will be set forth in the Registration Statement. These documents are available free of charge at the SEC's website at [www.sec.gov](http://www.sec.gov) or by directing a request to Artisan Acquisition Corp., Room 1111, New World Tower 1, 18 Queen's Road, Central, Hong Kong.

**No Offer or Solicitation**

This document is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and does not constitute an offer to sell or a solicitation of an offer to buy any securities of Artisan, Prenetics or PubCo, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

---